Thoughts on Cilta-cel US Delay
Yesterday’s PDUFA delay for JNJ/Legend’s BCMA CAR-T product cilta-cel was unexpected (see previous insight), and it brings up some potentially relevant questions. Below, Celltelligence discusses if the benefit to BMS is as obvious as one may think.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.